“There are signals that GLP-1s could be the first true longevity drug,” Alex Zhavoronkov, the founder and CEO of Insilico Medicine, said at the #Fortune Innovation Forum in Kuala Lumpur, Malaysia. Top scientists from both Novo Nordisk and Eli Lilly have suggested that GLP-1s could have broader effects than just tackling obesity and diabetes. “They found that the regular intake of this drug may reduce the incidence of many age-related diseases, including some CNS (central nervous system) disorders, liver disease, and kidney disease,” Zhavoronkov said. Read more: https://lnkd.in/gDN4JBsN
Fortune’s Post
More from this author
-
Facebook cofounder says being a CEO was ‘exhausting’—like 82% of bosses, he never intended to manage people
-
‘Big Bang Theory’ star had an existential crisis after his big break—despite making $1 million an episode
-
Self-made millionaire behind $4 billion Skims says it all began with a cold call to Kris Jenner